5,151 Shares in Insmed Incorporated (NASDAQ:INSM) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,151 shares of the biopharmaceutical company’s stock, valued at approximately $376,000.

Several other large investors have also bought and sold shares of the stock. WCM Investment Management LLC raised its position in Insmed by 58.6% during the 3rd quarter. WCM Investment Management LLC now owns 148,330 shares of the biopharmaceutical company’s stock worth $10,751,000 after purchasing an additional 54,806 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of Insmed by 164.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 10,179 shares of the biopharmaceutical company’s stock worth $743,000 after acquiring an additional 6,335 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of Insmed by 5.2% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 59,623 shares of the biopharmaceutical company’s stock worth $4,352,000 after acquiring an additional 2,962 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Insmed in the 3rd quarter worth about $35,322,000. Finally, Atria Investments Inc raised its position in shares of Insmed by 61.7% in the 3rd quarter. Atria Investments Inc now owns 4,985 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 1,902 shares in the last quarter.

Insmed Price Performance

Shares of NASDAQ INSM opened at $73.81 on Friday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The stock’s 50 day moving average price is $72.07 and its 200-day moving average price is $65.65. The company has a market capitalization of $13.20 billion, a PE ratio of -13.30 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the previous year, the firm earned ($1.10) EPS. The firm’s revenue was up 18.1% on a year-over-year basis. On average, equities analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The trade was a 27.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. This trade represents a 29.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock worth $5,765,446 in the last 90 days. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

INSM has been the subject of several research analyst reports. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. TD Cowen raised their target price on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. UBS Group raised their target price on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus raised their target price on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.07.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.